

1                    **CYTOTOXICITY MEDIATION OF CELLS EVIDENCING SURFACE**

2                    **EXPRESSION OF CD63**

3  
4                    Reference to Related Applications:

5                    This application is a continuation-in-part of application S.N. 10/603,006, filed June  
6                    23, 2003, which is a continuation-in-part of application S.N. 10/348,231, filed January 21,  
7                    *issued as US Patent NO.: 7,009,040*  
2003, the contents of each of which are herein incorporated by reference.

8                    Field Of The Invention:

9                    This invention relates to the diagnosis and treatment of cancerous diseases,  
10                   particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use  
11                   of cancerous disease modifying antibodies (CDMAB), optionally in combination with one  
12                   or more chemotherapeutic agents, as a means for initiating the cytotoxic response. The  
13                   invention further relates to binding assays, which utilize the CDMAB of the instant  
14                   invention.

15                   Background Of The Invention:

16                   CD63 is a Type III membrane protein of the tetraspanin family whose 20 current  
17                   members are characterized by the presence of four transmembrane segments. Several  
18                   groups independently identified CD63, using antibodies raised to whole cell preparations  
19                   of activated platelets, granulocytes, and melanoma cells. Cloning of the respective cDNAs  
20                   of their cognate glycoprotein antigens led to the recognition that the different antigens  
21                   were one and the same molecule. The Sixth International Workshop on Leukocyte Typing  
22                   (1996) subsequently categorized these antibodies as CD63 antibodies. Prior to the 1996  
23                   Workshop, CD63 was known by multiple names (melanoma 1 antigen, ocular melanoma-  
24                   associated antigen, melanoma associated antigen ME491, lysosome-associated membrane  
McHale & Slavin, P.A.

2056.039

Express Mail No. EV303518101US